Mizuho analyst Irina Koffler lowered her price target for Allergan to $200 citing the company’s “disappointing” 2019 guidance. The analyst, however, says her thesis remains unchanged and she keeps a Buy rating the stock. Koffler still sees Allergan shares as attractively valued and she believes company has a number of catalysts to help it recover throughout the year.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.